Table 5.
Mean change from baseline in CFT at 6 months
| Outcome of interest | Studies (n) | WMD (95% CI) | P | Study heterogeneity | ||
|---|---|---|---|---|---|---|
| χ2 | P | I 2 | ||||
| IVR 0.5 mg vs non-anti-VEGF | ||||||
| Type of RVO | ||||||
| All trials | 4 | −216.86 (−279.01, −154.71) | <0.001 | 5.57 | 0.135 | 46.1% |
| CRVO | 2 | −230.84 (−357.63, −104.06) | <0.001 | 3.03 | 0.082 | 67.0% |
| BRVO | 2 | −190.05 (−243.33, −136.78) | <0.001 | 0.07 | 0.789 | 0.00% |
| Sample size | 4 | −216.86 (−279.01, −154.71) | <0.001 | 5.57 | 0.135 | 46.1% |
| >100 | 2 | −233.77 (−328.83, −138.72) | <0.001 | 4.49 | 0.034 | 77.7% |
| <100 | 2 | −175.95 (−277.40, −74.50) | <0.001 | 0.30 | 0.585 | 0.00% |
| Different non-anti-VEGF treatment | ||||||
| All trials | 4 | −216.86 (−279.01, −154.71) | <0.001 | 5.57 | 0.135 | 46.1% |
| Sham | 3 | −216.42 (−292.99, −139.85) | <0.001 | 5.56 | 0.062 | 64.0% |
| Sham plus laser | 1 | −210.84 (−371.90, −49.79) | <0.001 | - | ||
| IVR 0.5 mg vs IVR 0.3 mg | 2 | −12.26 (−55.60, 31.08) | 0.579 | 0.06 | 0.812 | 0.00% |
| IVR 0.3 mg vs non-anti-VEGF | 2 | −218.97 (−303.31, −134.63) | <0.001 | 3.39 | 0.066 | 70.5% |
CFT = central foveal thickness; WMD = weighted mean differences; CI = confidence interval; IVR = intravitreal ranibizumab; VEGF = vascular endothelial growth factor; RVO = retinal vein occlusion; CRVO = central retinal vein occlusion; BRVO = branch retinal vein occlusion.